FREE SHIPPING over $40
OVER 10000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Journal of virology2002; 76(21); 10588-10597; doi: 10.1128/jvi.76.21.10588-10597.2002

Equine infectious anemia virus envelope evolution in vivo during persistent infection progressively increases resistance to in vitro serum antibody neutralization as a dominant phenotype.

Abstract: Equine infectious anemia virus (EIAV) infection of horses is characterized by well-defined waves of viremia associated with the sequential evolution of distinct viral populations displaying extensive envelope gp90 variation; however, a correlation of in vivo envelope evolution with in vitro serum neutralization phenotype remains undefined. Therefore, the goal of the present study was to utilize a previously defined panel of natural variant EIAV envelope isolates from sequential febrile episodes to characterize the effects of envelope variation during persistent infection on viral neutralization phenotypes and to define the determinants of EIAV envelope neutralization specificity. To assess the neutralization phenotypes of the sequential EIAV envelope variants, we determined the sensitivity of five variant envelopes to neutralization by a longitudinal panel of immune serum from the source infected pony. The results indicated that the evolution of the EIAV envelope sequences observed during sequential febrile episodes produced an increasingly neutralization-resistant phenotype. To further define the envelope determinants of EIAV neutralization specificity, we examined the neutralization properties of a panel of chimeric envelope constructs derived from reciprocal envelope domain exchanges between selected neutralization-sensitive and neutralization-resistant envelope variants. These results indicated that the EIAV gp90 V3 and V4 domains individually conferred serum neutralization resistance while other envelope segments in addition to V3 and V4 were evidently required for conferring total serum neutralization sensitivity. These data clearly demonstrate for the first time the influence of sequential gp90 variation during persistent infection in increasing envelope neutralization resistance, identify the gp90 V3 and V4 domains as the principal determinants of antibody neutralization resistance, and indicate distinct complex cooperative envelope domain interactions in defining sensitivity to serum antibody neutralization.
Get Full Text
Publication Date: 2002-10-09 PubMed ID: 12368301PubMed Central: PMC136617DOI: 10.1128/jvi.76.21.10588-10597.2002Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Research Support
  • Non-U.S. Gov't
  • Research Support
  • U.S. Gov't
  • P.H.S.

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research investigates how the Equine Infectious Anemia Virus (EIAV) evolves in horses over time to become increasingly resistant to immune system responses. Its findings point to specific parts of the virus—known as the gp90 V3 and V4 domains—as the main contributors to this resistance, increasing our understanding of this disease and potentially informing future treatment strategies.

Understanding EIAV Evolution and Resistance

The Equine Infectious Anemia Virus (EIAV) presents in horses in waves of viremia (viral presence in the bloodstream), each characterized by different viral populations showcasing various envelope variations. These variations in the envelope of the virus, specifically gp90, were found to increase the virus’s resistance to neutralization by antibodies in the horse’s serum over time, signifying an evolution of the virus within the host. This progression was tracked using a series of natural EIAV envelope variants taken from sequential episodes of fever in the infected horse.

  • The panel of natural EIAV envelope variants was used to study the effects of envelope variations on viral neutralization.
  • Five different envelope variants were assessed for their sensitivity to neutralization by using a series of immune sera from the source horse. Results showed that increased envelope sequence variations over time resulted in an increasingly neutralization-resistant phenotype.

Identifying Key Envelope Variants

In order to determine the specific envelope properties that gave rise to neutralization resistance, the researchers examined a series of chimera constructs. These constructs were the result of domain exchanges between different envelopes, ranging from neutralization-sensitive to neutralization-resistant variants.

  • The gp90 V3 and V4 domains within the EIAV envelope were identified as the main contributors to serum neutralization resistance.
  • However, other envelope segments alongside V3 and V4 also played a crucial part in total serum neutralization sensitivity, suggesting that there a complex interplay of envelope attributes that influence sensitivity to serum antibody neutralization.

The research concludes by establishing the gp90 V3 and V4 domains’ crucial role in antibody neutralization resistance and noting the complicated interaction of envelope domain elements in defining sensitivity to serum antibody neutralization. These findings provide critical insights into EIAV evolution during persistent infection, enhancing our understanding of the virus’s survival mechanisms and informing potential countermeasures.

Cite This Article

APA
Howe L, Leroux C, Issel CJ, Montelaro RC. (2002). Equine infectious anemia virus envelope evolution in vivo during persistent infection progressively increases resistance to in vitro serum antibody neutralization as a dominant phenotype. J Virol, 76(21), 10588-10597. https://doi.org/10.1128/jvi.76.21.10588-10597.2002

Publication

Journal of virology
ISSN: 0022-538X
NlmUniqueID: 0113724
Country: United States
Language: English
Volume: 76
Issue: 21
Pages: 10588-10597

Researcher Affiliations

Howe, Laryssa
  • Department of Infectious Disease and Microbiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, USA.
Leroux, Caroline
    Issel, Charles J
      Montelaro, Ronald C

        MeSH Terms

        • Amino Acid Sequence
        • Animals
        • Antibodies, Viral / blood
        • Antibodies, Viral / immunology
        • Directed Molecular Evolution
        • Disease Progression
        • Epitope Mapping
        • Epitopes, B-Lymphocyte / genetics
        • Epitopes, B-Lymphocyte / immunology
        • Equine Infectious Anemia / physiopathology
        • Equine Infectious Anemia / virology
        • Glycoproteins / genetics
        • Glycoproteins / immunology
        • Horses
        • Immunodominant Epitopes / genetics
        • Immunodominant Epitopes / immunology
        • Infectious Anemia Virus, Equine / genetics
        • Infectious Anemia Virus, Equine / immunology
        • Molecular Sequence Data
        • Neutralization Tests
        • Phenotype
        • Viral Envelope Proteins / genetics
        • Viral Envelope Proteins / immunology

        Grant Funding

        • R01 AI025850 / NIAID NIH HHS
        • R01 AI25850 / NIAID NIH HHS

        References

        This article includes 36 references
        1. Ball JM, Rushlow KE, Issel CJ, Montelaro RC. Detailed mapping of the antigenicity of the surface unit glycoprotein of equine infectious anemia virus by using synthetic peptide strategies.. J Virol 1992 Feb;66(2):732-42.
          pmc: PMC240772pubmed: 1370556doi: 10.1128/jvi.66.2.732-742.1992google scholar: lookup
        2. Beaumont T, van Nuenen A, Broersen S, Blattner WA, Lukashov VV, Schuitemaker H. Reversal of human immunodeficiency virus type 1 IIIB to a neutralization-resistant phenotype in an accidentally infected laboratory worker with a progressive clinical course.. J Virol 2001 Mar;75(5):2246-52.
          pmc: PMC114808pubmed: 11160728doi: 10.1128/jvi.75.5.2246-2252.2001google scholar: lookup
        3. Burns DP, Collignon C, Desrosiers RC. Simian immunodeficiency virus mutants resistant to serum neutralization arise during persistent infection of rhesus monkeys.. J Virol 1993 Jul;67(7):4104-13.
          pmc: PMC237779pubmed: 8510218doi: 10.1128/jvi.67.7.4104-4113.1993google scholar: lookup
        4. Chackerian B, Rudensey LM, Overbaugh J. Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies.. J Virol 1997 Oct;71(10):7719-27.
          pmc: PMC192123pubmed: 9311856doi: 10.1128/jvi.71.10.7719-7727.1997google scholar: lookup
        5. Chen M, Shi C, Kalia V, Tencza SB, Montelaro RC, Gupta P. HIV gp120 V(1)/V(2) and C(2)-V(3) domains glycoprotein compatibility is required for viral replication.. Virus Res 2001 Nov 5;79(1-2):91-101.
          pubmed: 11551649doi: 10.1016/s0168-1702(01)00322-7google scholar: lookup
        6. Cheng-Mayer C, Brown A, Harouse J, Luciw PA, Mayer AJ. Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation.. J Virol 1999 Jul;73(7):5294-300.
          pmc: PMC112584pubmed: 10364275doi: 10.1128/jvi.73.7.5294-5300.1999google scholar: lookup
        7. Cook RF, Berger SL, Rushlow KE, McManus JM, Cook SJ, Harrold S, Raabe ML, Montelaro RC, Issel CJ. Enhanced sensitivity to neutralizing antibodies in a variant of equine infectious anemia virus is linked to amino acid substitutions in the surface unit envelope glycoprotein.. J Virol 1995 Mar;69(3):1493-9.
          pmc: PMC188739pubmed: 7853482doi: 10.1128/jvi.69.3.1493-1499.1995google scholar: lookup
        8. Cook RF, Leroux C, Cook SJ, Berger SL, Lichtenstein DL, Ghabrial NN, Montelaro RC, Issel CJ. Development and characterization of an in vivo pathogenic molecular clone of equine infectious anemia virus.. J Virol 1998 Feb;72(2):1383-93.
          pmc: PMC124617pubmed: 9445039doi: 10.1128/jvi.72.2.1383-1393.1998google scholar: lookup
        9. Craigo JK, Leroux C, Howe L, Steckbeck JD, Cook SJ, Issel CJ, Montelaro RC. Transient immune suppression of inapparent carriers infected with a principal neutralizing domain-deficient equine infectious anaemia virus induces neutralizing antibodies and lowers steady-state virus replication.. J Gen Virol 2002 Jun;83(Pt 6):1353-1359.
          pubmed: 12029150doi: 10.1099/0022-1317-83-6-1353google scholar: lookup
        10. Fujimiya Y, Perryman LE, Crawford TB. Leukocyte cytotoxicity in a persistent virus infection: presence of direct cytotoxicity but absence of antibody-dependent cellular cytotoxicity in horses infected with equine infectious anemia virus.. Infect Immun 1979 Jun;24(3):628-36.
          pmc: PMC414352pubmed: 223981doi: 10.1128/iai.24.3.628-636.1979google scholar: lookup
        11. Gerencer M, Valpotić I, Jukić B, Tomasković M, Basić I. Qualitative analyses of cellular immune functions in equine infectious anemia show homology with AIDS.. Arch Virol 1989;104(3-4):249-57.
          pubmed: 2523215doi: 10.1007/bf01315547google scholar: lookup
        12. Hammond SA, Cook SJ, Lichtenstein DL, Issel CJ, Montelaro RC. Maturation of the cellular and humoral immune responses to persistent infection in horses by equine infectious anemia virus is a complex and lengthy process.. J Virol 1997 May;71(5):3840-52.
          pmc: PMC191535pubmed: 9094660doi: 10.1128/jvi.71.5.3840-3852.1997google scholar: lookup
        13. Hammond SA, Li F, McKeon BM Sr, Cook SJ, Issel CJ, Montelaro RC. Immune responses and viral replication in long-term inapparent carrier ponies inoculated with equine infectious anemia virus.. J Virol 2000 Jul;74(13):5968-81.
          pmc: PMC112093pubmed: 10846078doi: 10.1128/jvi.74.13.5968-5981.2000google scholar: lookup
        14. Harrold SM, Cook SJ, Cook RF, Rushlow KE, Issel CJ, Montelaro RC. Tissue sites of persistent infection and active replication of equine infectious anemia virus during acute disease and asymptomatic infection in experimentally infected equids.. J Virol 2000 Apr;74(7):3112-21.
          pmc: PMC111810pubmed: 10708426doi: 10.1128/jvi.74.7.3112-3121.2000google scholar: lookup
        15. Hussain KA, Issel CJ, Schnorr KL, Rwambo PM, Montelaro RC. Antigenic analysis of equine infectious anemia virus (EIAV) variants by using monoclonal antibodies: epitopes of glycoprotein gp90 of EIAV stimulate neutralizing antibodies.. J Virol 1987 Oct;61(10):2956-61.
          pmc: PMC255867pubmed: 2442410doi: 10.1128/jvi.61.10.2956-2961.1987google scholar: lookup
        16. Issel CJ, Adams WV Jr, Meek L, Ochoa R. Transmission of equine infectious anemia virus from horses without clinical signs of disease.. J Am Vet Med Assoc 1982 Feb 1;180(3):272-5.
          pubmed: 6276353
        17. Issel CJ, Foil LD. Studies on equine infectious anemia virus transmission by insects.. J Am Vet Med Assoc 1984 Feb 1;184(3):293-7.
          pubmed: 6321420
        18. Kono Y, Hirasawa K, Fukunaga Y, Taniguchi T. Recrudescence of equine infectious anemia by treatment with immunosuppressive drugs.. Natl Inst Anim Health Q (Tokyo) 1976 Spring;16(1):8-15.
          pubmed: 177894
        19. Leroux C, Craigo JK, Issel CJ, Montelaro RC. Equine infectious anemia virus genomic evolution in progressor and nonprogressor ponies.. J Virol 2001 May;75(10):4570-83.
          pmc: PMC114210pubmed: 11312327doi: 10.1128/jvi.75.10.4570-4583.2001google scholar: lookup
        20. Leroux C, Issel CJ, Montelaro RC. Novel and dynamic evolution of equine infectious anemia virus genomic quasispecies associated with sequential disease cycles in an experimentally infected pony.. J Virol 1997 Dec;71(12):9627-39.
          pmc: PMC230271pubmed: 9371627doi: 10.1128/jvi.71.12.9627-9639.1997google scholar: lookup
        21. Lichtenstein DL, Issel CJ, Montelaro RC. Genomic quasispecies associated with the initiation of infection and disease in ponies experimentally infected with equine infectious anemia virus.. J Virol 1996 Jun;70(6):3346-54.
          pmc: PMC190205pubmed: 8648664doi: 10.1128/jvi.70.6.3346-3354.1996google scholar: lookup
        22. McGuire TC, Tumas DB, Byrne KM, Hines MT, Leib SR, Brassfield AL, O'Rourke KI, Perryman LE. Major histocompatibility complex-restricted CD8+ cytotoxic T lymphocytes from horses with equine infectious anemia virus recognize Env and Gag/PR proteins.. J Virol 1994 Mar;68(3):1459-67.
          pmc: PMC236601pubmed: 8107209doi: 10.1128/jvi.68.3.1459-1467.1994google scholar: lookup
        23. Montelaro R, Ball JM, Rushlow K. Equine retroviruses. p. 257-360. In J. A. Levy (ed.), The Retroviridae. Plenum Press, New York, N.Y..
        24. Narayan SV, Mukherjee S, Jia F, Li Z, Wang C, Foresman L, McCormick-Davis C, Stephens EB, Joag SV, Narayan O. Characterization of a neutralization-escape variant of SHIVKU-1, a virus that causes acquired immune deficiency syndrome in pig-tailed macaques.. Virology 1999 Mar 30;256(1):54-63.
          pubmed: 10087226doi: 10.1006/viro.1999.9605google scholar: lookup
        25. Payne SL, Fang FD, Liu CP, Dhruva BR, Rwambo P, Issel CJ, Montelaro RC. Antigenic variation and lentivirus persistence: variations in envelope gene sequences during EIAV infection resemble changes reported for sequential isolates of HIV.. Virology 1987 Dec;161(2):321-31.
          pubmed: 2825406doi: 10.1016/0042-6822(87)90124-3google scholar: lookup
        26. Perryman LE, O'Rourke KI, McGuire TC. Immune responses are required to terminate viremia in equine infectious anemia lentivirus infection.. J Virol 1988 Aug;62(8):3073-6.
          pmc: PMC253753pubmed: 2839723doi: 10.1128/jvi.62.8.3073-3076.1988google scholar: lookup
        27. Rudensey LM, Kimata JT, Long EM, Chackerian B, Overbaugh J. Changes in the extracellular envelope glycoprotein of variants that evolve during the course of simian immunodeficiency virus SIVMne infection affect neutralizing antibody recognition, syncytium formation, and macrophage tropism but not replication, cytopathicity, or CCR-5 coreceptor recognition.. J Virol 1998 Jan;72(1):209-17.
          pmc: PMC109366pubmed: 9420217doi: 10.1128/jvi.72.1.209-217.1998google scholar: lookup
        28. Rwambo PM, Issel CJ, Adams WV Jr, Hussain KA, Miller M, Montelaro RC. Equine infectious anemia virus (EIAV) humoral responses of recipient ponies and antigenic variation during persistent infection.. Arch Virol 1990;111(3-4):199-212.
          pubmed: 2162160doi: 10.1007/bf01311054google scholar: lookup
        29. Rwambo PM, Issel CJ, Hussain KA, Montelaro RC. In vitro isolation of a neutralization escape mutant of equine infectious anemia virus (EIAV).. Arch Virol 1990;111(3-4):275-80.
          pubmed: 1693846doi: 10.1007/bf01311062google scholar: lookup
        30. Si Z, Cayabyab M, Sodroski J. Envelope glycoprotein determinants of neutralization resistance in a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2) derived by passage in monkeys.. J Virol 2001 May;75(9):4208-18.
          pmc: PMC114166pubmed: 11287570doi: 10.1128/jvi.75.9.4208-4218.2001google scholar: lookup
        31. Tschetter JR, Byrne KM, Perryman LE, McGuire TC. Control of equine infectious anemia virus is not dependent on ADCC mediating antibodies.. Virology 1997 Apr 14;230(2):275-80.
          pubmed: 9143283doi: 10.1006/viro.1997.8502google scholar: lookup
        32. Tumas DB, Hines MT, Perryman LE, Davis WC, McGuire TC. Corticosteroid immunosuppression and monoclonal antibody-mediated CD5+ T lymphocyte depletion in normal and equine infectious anaemia virus-carrier horses.. J Gen Virol 1994 May;75 ( Pt 5):959-68.
          pubmed: 7513746doi: 10.1099/0022-1317-75-5-959google scholar: lookup
        33. Ye Y, Si ZH, Moore JP, Sodroski J. Association of structural changes in the V2 and V3 loops of the gp120 envelope glycoprotein with acquisition of neutralization resistance in a simian-human immunodeficiency virus passaged in vivo.. J Virol 2000 Dec;74(24):11955-62.
          pmc: PMC112479pubmed: 11090196doi: 10.1128/jvi.74.24.11955-11962.2000google scholar: lookup
        34. Zhang W, Lonning SM, McGuire TC. Gag protein epitopes recognized by ELA-A-restricted cytotoxic T lymphocytes from horses with long-term equine infectious anemia virus infection.. J Virol 1998 Dec;72(12):9612-20.
          pmc: PMC110470pubmed: 9811694doi: 10.1128/jvi.72.12.9612-9620.1998google scholar: lookup
        35. Zheng YH, Nakaya T, Sentsui H, Kameoka M, Kishi M, Hagiwara K, Takahashi H, Kono Y, Ikuta K. Insertions, duplications and substitutions in restricted gp90 regions of equine infectious anaemia virus during febrile episodes in an experimentally infected horse.. J Gen Virol 1997 Apr;78 ( Pt 4):807-20.
          pubmed: 9129653doi: 10.1099/0022-1317-78-4-807google scholar: lookup
        36. Zheng YH, Sentsui H, Nakaya T, Kono Y, Ikuta K. In vivo dynamics of equine infectious anemia viruses emerging during febrile episodes: insertions/duplications at the principal neutralizing domain.. J Virol 1997 Jul;71(7):5031-9.
          pmc: PMC191736pubmed: 9188568doi: 10.1128/jvi.71.7.5031-5039.1997google scholar: lookup

        Citations

        This article has been cited 18 times.
        1. Lin Y, Wang XF, Wang Y, Du C, Ren H, Liu C, Zhu D, Chen J, Na L, Liu D, Yang Z, Wang X. Env diversity-dependent protection of the attenuated equine infectious anaemia virus vaccine. Emerg Microbes Infect 2020 Dec;9(1):1309-1320.
          doi: 10.1080/22221751.2020.1773323pubmed: 32525460google scholar: lookup
        2. Malossi CD, Fioratti EG, Cardoso JF, Magro AJ, Kroon EG, Aguiar DM, Borges AMCM, Nogueira MF, Ullmann LS, Araujo JP Jr. High Genomic Variability in Equine Infectious Anemia Virus Obtained from Naturally Infected Horses in Pantanal, Brazil: An Endemic Region Case. Viruses 2020 Feb 12;12(2).
          doi: 10.3390/v12020207pubmed: 32059508google scholar: lookup
        3. Han X, Zhang P, Yu W, Xiang W, Li X. Amino acid mutations in the env gp90 protein that modify N-linked glycosylation of the Chinese EIAV vaccine strain enhance resistance to neutralizing antibodies. Virus Genes 2016 Dec;52(6):814-822.
          doi: 10.1007/s11262-016-1382-2pubmed: 27572122google scholar: lookup
        4. Wang XF, Lin YZ, Li Q, Liu Q, Zhao WW, Du C, Chen J, Wang X, Zhou JH. Genetic Evolution during the development of an attenuated EIAV vaccine. Retrovirology 2016 Feb 3;13:9.
          doi: 10.1186/s12977-016-0240-6pubmed: 26842878google scholar: lookup
        5. Craigo JK, Ezzelarab C, Cook SJ, Liu C, Horohov D, Issel CJ, Montelaro RC. Protective efficacy of centralized and polyvalent envelope immunogens in an attenuated equine lentivirus vaccine. PLoS Pathog 2015 Jan;11(1):e1004610.
          doi: 10.1371/journal.ppat.1004610pubmed: 25569288google scholar: lookup
        6. Craigo JK, Montelaro RC. Lessons in AIDS vaccine development learned from studies of equine infectious, anemia virus infection and immunity. Viruses 2013 Dec 2;5(12):2963-76.
          doi: 10.3390/v5122963pubmed: 24316675google scholar: lookup
        7. Craigo JK, Ezzelarab C, Cook SJ, Chong L, Horohov D, Issel CJ, Montelaro RC. Envelope determinants of equine lentiviral vaccine protection. PLoS One 2013;8(6):e66093.
          doi: 10.1371/journal.pone.0066093pubmed: 23785473google scholar: lookup
        8. Craigo JK, Ezzelarab C, Montelaro RC. Development of a high throughput, semi-automated, infectious center cell-based ELISA for equine infectious anemia virus. J Virol Methods 2012 Nov;185(2):221-7.
          doi: 10.1016/j.jviromet.2012.07.007pubmed: 22820072google scholar: lookup
        9. Wu W, Blythe DC, Loyd H, Mealey RH, Tallmadge RL, Dorman KS, Carpenter S. Decreased infectivity of a neutralization-resistant equine infectious anemia virus variant can be overcome by efficient cell-to-cell spread. J Virol 2011 Oct;85(19):10421-4.
          doi: 10.1128/JVI.05349-11pubmed: 21752904google scholar: lookup
        10. Wang X, Wang S, Lin Y, Jiang C, Ma J, Zhao L, Lv X, Wang F, Shen R, Zhou J. Unique evolution characteristics of the envelope protein of EIAV(LN₄₀), a virulent strain of equine infectious anemia virus. Virus Genes 2011 Apr;42(2):220-8.
          doi: 10.1007/s11262-010-0563-7pubmed: 21369830google scholar: lookup
        11. Qi X, Wang X, Wang S, Lin Y, Jiang C, Ma J, Zhao L, Lv X, Shen R, Wang F, Kong X, Su Z, Zhou J. Genomic analysis of an effective lentiviral vaccine-attenuated equine infectious anemia virus vaccine EIAV FDDV13. Virus Genes 2010 Aug;41(1):86-98.
          doi: 10.1007/s11262-010-0491-6pubmed: 20526660google scholar: lookup
        12. Taylor SD, Leib SR, Carpenter S, Mealey RH. Selection of a rare neutralization-resistant variant following passive transfer of convalescent immune plasma in equine infectious anemia virus-challenged SCID horses. J Virol 2010 Jul;84(13):6536-48.
          doi: 10.1128/JVI.00218-10pubmed: 20392850google scholar: lookup
        13. Tagmyer TL, Craigo JK, Cook SJ, Even DL, Issel CJ, Montelaro RC. Envelope determinants of equine infectious anemia virus vaccine protection and the effects of sequence variation on immune recognition. J Virol 2008 Apr;82(8):4052-63.
          doi: 10.1128/JVI.02028-07pubmed: 18234792google scholar: lookup
        14. Craigo JK, Zhang B, Barnes S, Tagmyer TL, Cook SJ, Issel CJ, Montelaro RC. Envelope variation as a primary determinant of lentiviral vaccine efficacy. Proc Natl Acad Sci U S A 2007 Sep 18;104(38):15105-10.
          doi: 10.1073/pnas.0706449104pubmed: 17846425google scholar: lookup
        15. Mealey RH, Sharif A, Ellis SA, Littke MH, Leib SR, McGuire TC. Early detection of dominant Env-specific and subdominant Gag-specific CD8+ lymphocytes in equine infectious anemia virus-infected horses using major histocompatibility complex class I/peptide tetrameric complexes. Virology 2005 Aug 15;339(1):110-26.
          doi: 10.1016/j.virol.2005.05.025pubmed: 15979679google scholar: lookup
        16. Mealey RH, Leib SR, Pownder SL, McGuire TC. Adaptive immunity is the primary force driving selection of equine infectious anemia virus envelope SU variants during acute infection. J Virol 2004 Sep;78(17):9295-305.
          doi: 10.1128/JVI.78.17.9295-9305.2004pubmed: 15308724google scholar: lookup
        17. Payne SL, Pei XF, Jia B, Fagerness A, Fuller FJ. Influence of long terminal repeat and env on the virulence phenotype of equine infectious anemia virus. J Virol 2004 Mar;78(5):2478-85.
          doi: 10.1128/jvi.78.5.2478-2485.2004pubmed: 14963146google scholar: lookup
        18. Cole KS, Steckbeck JD, Rowles JL, Desrosiers RC, Montelaro RC. Removal of N-linked glycosylation sites in the V1 region of simian immunodeficiency virus gp120 results in redirection of B-cell responses to V3. J Virol 2004 Feb;78(3):1525-39.
          doi: 10.1128/jvi.78.3.1525-1539.2004pubmed: 14722307google scholar: lookup
        Subscribe to our newsletter
        Join 99,658 horse owners like you who receive our email updates on horse health and nutrition.